Literature DB >> 19913947

[Referral criteria for benign prostatic hyperplasia in primary care].

José María Molero1, David Pérez Morales, Francisco José Brenes Bermúdez, Esperanza Naval Pulido, Antonio Fernández-Pro, Juan Antonio Martín, Jesús Castiñeiras Fernández, José Manuel Cozar Olmo.   

Abstract

Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with International Prostate Symptom Score (IPSS) questionnaire, digital rectal examination and prostate-specific antigen (PSA) measurement are diagnostic tests available for general practitioners that allow setting a correct BPH diagnose. Patients with an IPSS<8 should be monitored by evaluating them annually. Treatment with alpha-blockers and an evaluation at the first and third month is recommended in patients with an IPSS 8-20 and if the prostate is small, if the prostate size is large treatment with alpha-blockers or 5alpha-reductase inhibitors and evaluation at the third and six month is recommended, and in patients with a large prostate and a PSA >1.5 ng/ml combined treatment and evaluation at the first and sixth month is recommended. Some clear criteria for referral to urology are established in this document, which help in the management of these patients. Those patients with BPH who do not show any improvement at the third month of treatment with alpha-blockers, or the sixth month with 5alpha-reductase inhibitors, will be referred to urology. Patients will also be referred to urology if they have lower urinary tract symptoms, a pathological finding during rectal examination, IPSS>20, PSA>10 ng/ml or PSA>4 ng/ml and free PSA<20% or if they are <50 years with suspected BHP, or if they have any urological complication. Copyright (c) 2009 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19913947      PMCID: PMC7022062          DOI: 10.1016/j.aprim.2009.07.006

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  35 in total

1.  [Cultural and linguistic validation, in Spanish, of the International Prostatic Symptoms Scale (I-PSS)].

Authors:  R Vela Navarrete; J M Martín Moreno; F J Calahorra; J Damián Moreno; A Hernández Coronado; P Boyle
Journal:  Actas Urol Esp       Date:  1994-09       Impact factor: 0.994

2.  Ten-language translation and harmonization of the International Prostate Symptom Score: developing a methodology for multinational clinical trials.

Authors:  X Badía; M García-Losa; R Dal-Ré
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

3.  Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA).

Authors: 
Journal:  Oncology (Williston Park)       Date:  2000-02       Impact factor: 2.990

4.  [Validity of tests for initial diagnosis and its concordance with final diagnosis in patients with suspected benign prostatic hyperplasia].

Authors:  J Carballido Rodríguez; X Badia Llach; A Gimeno Collado; L Regadera Anechina; L Regadera Sejas; R Dal-Ré Saavedra; M Guilera Sardá
Journal:  Actas Urol Esp       Date:  2006 Jul-Aug       Impact factor: 0.994

5.  A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.

Authors:  B Djavan; M Marberger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

6.  Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.

Authors:  Gerald L Andriole; Michael Marberger; Claus G Roehrborn
Journal:  J Urol       Date:  2006-05       Impact factor: 7.450

7.  Prostate-specific antigen test in diagnostic evaluation of chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Robert B Nadler; Mary McNaughton Collins; Kathleen J Propert; Stephen D Mikolajczyk; Jill S Knauss; J Richard Landis; Jackson E Fowler; Anthony J Schaeffer; Richard B Alexander
Journal:  Urology       Date:  2006-01-25       Impact factor: 2.649

8.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

Authors:  J E Oesterling; S J Jacobsen; C G Chute; H A Guess; C J Girman; L A Panser; M M Lieber
Journal:  JAMA       Date:  1993-08-18       Impact factor: 56.272

9.  Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men.

Authors:  S J Jacobsen; C J Girman; H A Guess; T Rhodes; J E Oesterling; M M Lieber
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450

Review 10.  Etiology and disease process of benign prostatic hyperplasia.

Authors:  J T Isaacs; D S Coffey
Journal:  Prostate Suppl       Date:  1989
View more
  4 in total

1.  [Benign prostatic hyperplasia referral criteria for primary care, 2011 version].

Authors:  José María Molero García; David Pérez Morales; Francisco Brenes Bermúdez; Esperanza Naval Pulido; Antonio Fernández-Pro Pedraza; Juan Antonio Martín Jiménez; Jesús Castiñeiras Fernández; José Manuel Cozar Olmo
Journal:  Aten Primaria       Date:  2011-10-22       Impact factor: 1.137

2.  [Alpha1-adrenogenic blockers and intraoperative floppy iris syndrome].

Authors:  Sonia Delgado Gallego; Francisco José Pérez Molto; José Luis Cuadrado Escamilla; Amparo Soriano Lafarge
Journal:  Aten Primaria       Date:  2011-03-11       Impact factor: 1.137

3.  [Quality of care indicators for benign prostatic hyperplasia. A qualitative study].

Authors:  Jorge Navarro-Pérez; Salvador Peiró; Francisco Brotons-Muntó; Emilio López-Alcina; Arcadio Real-Romaguera
Journal:  Aten Primaria       Date:  2013-12-15       Impact factor: 1.137

4.  Real-world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain.

Authors:  José María Molero; Bernardino Miñana; Juan Manuel Palacios-Moreno; Miguel Téllez Martínez-Fornes; David Lorite Mingot; Alfonso Agra Rolán; Ágata Carreño; Rafael Cuervo Pinto
Journal:  Int J Clin Pract       Date:  2020-08-16       Impact factor: 3.149

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.